Cell and gene therapies offer treatment, and sometimes cures, for patients with serious, often rare, and never-before-addressed diseases. And many more have become available in recent years—more than 75 launched worldwide in 2019, and 96 new ones were on track for the end of 2020.
Source: McKinsey & Co.
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more
